S1046 Predicting Histological Diagnosis After Endoscopic Submucosal Dissection With Demographic Characteristics and Endoscopic Lesion Characteristics: An Analysis of a Large Cohort in North America

guided therapy of GV in primary and secondary prophylaxis. Calculation was done by standard meta-analysis methodology using the random-effects model and heterogeneity was assessed using the I2% statistics. Results: A total of 13 studies were included in the final analysis. The EUS guided treatment efficacy of primary prophylaxis was 95% (95% CI [85.7-98.4%]) and secondary prophylaxis was 94.3% [83.698.1]. GV obliteration was 68.3% [43.4-85.8] for primary prophylaxis and 65.8% [38.8-85.4] for secondary prophylaxis. GV recurrence was 10% [2.5-32.8] in primary prophylaxis and 4.3% [1.710.5] in secondary prophylaxis. Early re-bleeding was seen in 6.7% [1.7-23.1] of primary prophylaxis cases and 5.5% [2.3-12.6] of secondary prophylaxis. Late re-bleeding was seen in 6% [2.3-14.9] of primary prophylaxis cases and 12.6% [9.3-16.8] of secondary prophylaxis cases. We conducted subgroup analysis with respect to studies published as abstracts and full manuscripts, and by sample-size. The results summarized in Table 1. Conclusion: Our meta-analysis study illustrates that EUS-guided therapy of GV may demonstrate excellent short and long-term clinical outcomes in both primary and secondary prophylaxis. This was shown by high EUS guided treatment efficacy of 95% and 94.3% in primary and secondary prophylaxis respectively. In addition, a low GV recurrence of 4.5% in secondary prophylaxis is a key positive finding; however, the late re-bleeding rate of 12.6% in secondary prophylaxis needs further evaluation and future study. Nevertheless, our study highlights that early EUS-guided therapy should be considered in the treatment of GV regardless of primary or secondary prophylaxis.